McKesson Corporation (MCK)
NYSE: MCK · Real-Time Price · USD
693.98
+4.62 (0.67%)
At close: Apr 14, 2025, 4:00 PM
689.90
-4.08 (-0.59%)
Pre-market: Apr 15, 2025, 7:49 AM EDT
McKesson Revenue
McKesson had revenue of $95.29B in the quarter ending December 31, 2024, with 17.80% growth. This brings the company's revenue in the last twelve months to $344.58B, up 14.29% year-over-year. In the fiscal year ending March 31, 2024, McKesson had annual revenue of $308.95B with 11.65% growth.
Revenue (ttm)
$344.58B
Revenue Growth
+14.29%
P/S Ratio
0.26
Revenue / Employee
$6,756,529
Employees
51,000
Market Cap
86.97B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 308.95B | 32.24B | 11.65% |
Mar 31, 2023 | 276.71B | 12.75B | 4.83% |
Mar 31, 2022 | 263.97B | 25.74B | 10.80% |
Mar 31, 2021 | 238.23B | 7.18B | 3.11% |
Mar 31, 2020 | 231.05B | 16.73B | 7.81% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MCK News
- 5 days ago - These 20 stocks have risen during Trump's trade tirade. Analysts see up to 30% additional upside. - Market Watch
- 6 days ago - Registration Opens for Annual McKesson ideaShare Conference - Business Wire
- 7 days ago - Sit Out The Crash With These 5 Dividend Stocks - Benzinga
- 10 days ago - 3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock - Barrons
- 12 days ago - McKesson Shares Up Over 2% After Key Signal - Benzinga
- 12 days ago - McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns. - Barrons
- 12 days ago - McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC - Business Wire
- 21 days ago - McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025 - Seeking Alpha